Two years adherence to anti-osteoporotic medications in postmenopausal Israeli women

Archives of Gerontology and Geriatrics

Volumn 49, Issue 3, 2009, Pages 360-363

  Segal, Elena ^a   Ish Shalom, Sophia ^b  

^a Metabolic Bone Diseases Unit   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Adherence to anti osteoporotic treatment; Anti resorbing agents; Fracture prevention; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM CARBONATE; RALOXIFENE; VITAMIN D;

ABDOMINAL PAIN; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DECISION MAKING; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FLUSHING; FOLLOW UP; FRAGILITY FRACTURE; GASTROINTESTINAL TOXICITY; HEALTH SURVEY; HUMAN; ISRAEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; THROMBOEMBOLISM;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; ISRAEL; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; RALOXIFENE; TIME FACTORS;

EID: 69349086213     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2008.11.016     Document Type: Article

References (21)

1. Brankin E., Walker M., Lynch N., Aspray T., Lis Y., and Cowell W. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr. Med. Opin. 7 (2006) 1249-1256
2. Burrell C.D., and Levy R.A. Therapeutic consequences of noncompliance. Improving Medication Compliance. Proceedings of a Symposium. National Pharmaceutical Council, Reston (1984) 7-16
3. Clowes J.A., Peel N.F., and Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab. 89 (2004) 1117-1123
4. Conrad P. The meaning of medications: another look at compliance. Soc. Sci. Med. 20 (1985) 29-37
5. Cramer J.A. Enhancing patient compliance in the elderly: role of packaging aids and monitoring. Drugs Aging 12 (1998) 7-15
6. Cramer J.A., Amonkar M.M., Hebborn A., and Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr. Med. Res. Opin. 21 (2005) 1453-1460
7. Downey T.W., Foltz S.H., Boccuzzi S.J., Omar M.A., and Kahler K.H. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. Southern Med. J. 99 (2006) 570-575
8. Ettinger B., Pressman A., and Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am. J. Manage. Care 4 (1998) 1377-1382
9. Eriksson M., Hadell K., Holme I., Walldius G., and Kjellstrom T. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. Intern. Med. 243 (1998) 373-380
10. Hughes C.M. Medication non-adherence in the elderly: how big is the problem?. Drugs Aging 21 (2004) 793-811
11. Kayser J., Ettinger B., and Pressman A. Postmenopausal hormonal support: discontinuation raloxifene versus estrogen. Menopause 8 (2001) 328-332
12. Masi L., and Bilezikian J.P. Osteoporosis: new hope for the future. Int. J. Fertil. Womens Med. 42 (1997) 245-254
13. MacLaughlin E.J., Raehl C.L., Treadway A.K., Sterling T.L., Zoller D.P., and Bond C.A. Assessing medication adherence in the elderly: which tools to use in clinical practice?. Drugs Aging 22 (2005) 231-255
14. Noncompliance with medications: an economic tragedy with important implications for health care reform. A Report by the Task Force for Compliance, November 1993, rev. April 1994. Available at: http://www.npcnow.org/resources/PDFs/Noncompliance.pdf. Accessed: November 5, 2008.
15. Penning-van Beest F.J., Goettsch W.G., Erkens J.A., and Herings R.M. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin. Ther. 28 (2006) 236-242
16. Peterson A.M., Takiya L., and Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am. J. Health-Syst. Pharm. 60 (2003) 657-665
17. Recker R.R., Gallagher R., and MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin. Proc. 80 (2005) 856-861
18. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Ronx C., Brandi M.L., Lund B., Ethgen D., Pack S., Roumagnac I., and Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 11 (2000) 83-91
19. Segal E., Tamir A., and Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr. Med. Assoc. J. 5 (2003) 859-862
20. Turbi C., Herrero-Beaumont G., Acebes J.C., Torrijos A., Grana J., Miguelez R., Sacristan J., and Marin F. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin. Ther. 26 (2004) 245-256
21. Weycker D., Macarios D., Edelsberg J., and Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos. Int. 17 (2006) 1645-1652